{
  "id": 4638395,
  "title": "H.C. Wainwright reiterates CRISPR Therapeutics stock rating at buy",
  "url": "https://urgent.news/2026/08/31/h-c-wainwright-reiterates-crispr-therapeutics-stock-rating-at-buy",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-31T11:42:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-crispr-therapeutics-stock-rating-at-buy-93CH-4882615"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has maintained its Buy rating and set a $80 price target for CRISPR Therapeutics (NASDAQ:CRSP). The stock's potential upside is estimated at 34% from its current price of $57.72. The company's market capitalization stands at $5.58 billion. CRISPR Therapeutics recently shared updated Phase 1a data from 15 patients. The data showed significant reductions in various biomarkers, with a 78.6% reduction in ANGPTL3, 52.5% reduction in LDL-C, and 47.8% reduction in triglycerides after one year. The company also announced a flat dose strategy for Phase 1b trials, aiming for an exposure equivalent to 0.8 mg/kg. H.C. Wainwright has not altered its estimates, valuation, or the 25% approval probability for CTX310. They anticipate the next catalyst for CTX310 to be the Phase 1b sHTG cohort update in the second half of 2026. Novartis and Ionis are expected to release HORIZON Lp(a) data in the same period. Investors interested in a more detailed analysis can refer to the comprehensive InvestingPro Research Reports covering CRISPR Therapeutics among over 1,400 US equities. Additionally, Citizens has also upgraded its rating on CRISPR Therapeutics to Market Outperform with an $80.00 price target, highlighting the company's progress in developing late-stage assets for cardiovascular and metabolic indications. The FDA's label expansion for CRISPR Therapeutics' gene therapy, CASGEVY, to include patients two years and older with sickle cell disease and transfusion-dependent beta-thalassemia could potentially increase the total addressable market by 10-15%.",
  "summary": null,
  "key_points": [
    "H.C. Wainwright maintains Buy rating for CRISPR Therapeutics",
    "Stock target price set at $80 with 34% upside potential",
    "Phase 1a data shows significant biomarker reductions in 15 patients"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "H.C. Wainwright reiterates Gain Therapeutics stock rating at buy",
        "url": "https://urgent.news/2026/08/31/h-c-wainwright-reiterates-gain-therapeutics-stock-rating-at-buy",
        "published": "2026-08-31T11:42:44.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}